Back to Awarded Treatment Trials
Awarded Trial: 01T-099
Grant ID
01T-099
Illness
Schizophrenia
Primary Drug/Intervention
Risperidone
Primary Dosage
0.5mg/d - 20mg/d
Secondary Drug Intervention
Olanzapine
Secondary Dosage
2.5mg/d-20mg/d
Other Drug/Intervention
Molindone
Other Dosage
10mg/d-140mg/d
Status
Completed
Investigator
McClellan
Sample Size
120
Duration of Study Period for Each Subject
8-44 weeks
Outcome Measurements
CGI, KID-SCID, PANSS, BPRS-C, MOSES, EPSE, SAEPS, Barnes Akathisia Scales, AIMS, CGAS, YSR, CBCL, CAFAS, QLS, WRAT
Results
N/A
Publication
Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L, Ambler D, Puglia M, Maloney AE, Michael E, De Jong S, Slifka K, Noyes N, Hlastala S, Pierson L, McNamara NK, Delporto-Bedoya D, Anderson R, Hamer RM, Lieberman JA. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry. 2008 Nov;165(11):1420-31.
Link
http://www.ncbi.nlm.nih.gov/pubmed/18794207
PI Name
Jon McClellan
Degree
MD
Center
Children's Hospital, Department of Child Psychiatry
Institution
University of Washington
Address
Box 359300, CH-13, 4800 Sand Point Way NE
City or Town
Seattle
State or Province
WA
Zip or Postal Code
98105
Country
USA
Email Address
drjack@u.washington.edu